$487 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDCO | New | MEDICINES COput | $25,455,000 | – | 750,000 | +100.0% | 5.23% | – |
| TXMD | New | THERAPEUTICSMD INC | $18,903,000 | – | 3,276,010 | +100.0% | 3.88% | – |
| TRVN | New | TREVENA INC | $17,644,000 | – | 3,000,650 | +100.0% | 3.62% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INC | $14,450,000 | – | 1,000,000 | +100.0% | 2.97% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $7,787,000 | – | 270,000 | +100.0% | 1.60% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $4,354,000 | – | 350,000 | +100.0% | 0.89% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALScall | $3,165,000 | – | 500,000 | +100.0% | 0.65% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $1,944,000 | – | 51,935 | +100.0% | 0.40% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| CYTOKINETICS INC | 18 | Q2 2024 | 7.1% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Context Therapeutics Inc. | June 05, 2024 | 7,419,355 | 9.9% |
| Outlook Therapeutics, Inc. | April 08, 2024 | 2,231,324 | 10.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 3,703,433 | 6.4% |
| Avalo Therapeutics, Inc. | February 14, 2024 | 2,085 | 0.3% |
| HERON THERAPEUTICS, INC. /DE/Sold out | February 14, 2024 | 0 | 0.0% |
| Neurogene Inc. | February 14, 2024 | 994,229 | 7.8% |
| OptiNose, Inc. | February 14, 2024 | 11,484,120 | 10.0% |
| PRECISION BIOSCIENCES INCSold out | February 14, 2024 | 0 | 0.0% |
| UroGen Pharma Ltd. | February 14, 2024 | 2,620,545 | 8.5% |
| Vistagen Therapeutics, Inc. | February 14, 2024 | 2,792,927 | 10.0% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| SC 13G | 2024-08-15 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-08-05 |
| SC 13G | 2024-07-18 |
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.